TY - JOUR
T1 - POCT PT INR — Is it adequate for patient care? A comparison of the Roche Coaguchek XS vs. Stago Star vs. Siemens BCS in patients routinely seen in an anticoagulation clinic
AU - Baker, Wendy S.
AU - Albright, Kathleen J.
AU - Berman, Megan
AU - Spratt, Heidi
AU - Mann, Peggy A.
AU - Unabia, Jaime
AU - Petersen, John R.
PY - 2017/9/1
Y1 - 2017/9/1
N2 - Background In this study we examined the difference in patient INR values as measured by the POCT CoaguChek XS device and central laboratory Stago Evolution and Siemens BCS XP analyzers. Methods This study composed of 100 warfarin therapy patients and 20 coagulation normal subjects, showed that the difference between the POCT and clinical laboratory values increased with increasing INR and was exacerbated by the use of different thromboplastin reagents by the POCT and central lab. Results The CoaguChek XS and on-site Stago analyzers which used human recombinant (ISI = 1.01) and rabbit brain thromboplastin (ISI = 1.25), respectively, showed reasonable agreement for INR < 3.0 (k = 0.62) but significant difference for INR ≥ 3.0 (k = 0.10). In contrast, the CoaguChek XS and Siemens BCS XP, which both employed human recombinant thromboplastin (BCS ISI = 1.02), showed greater agreement for the complete range INR values (INR < 3.0 k = 0.84; INR ≥ 3.0 k = 0.70). ECAA Poller calibrant data showed the automated instruments were performing as expected, indicating that ISI calibrations were correct but insufficient to standardize the INR values for the different thromboplastin methods across the full range of measured INRs. Central lab verification of POCT INR > 5.0 with the Stago Evolution prevented adverse treatment events for the warfarin therapy patients in the six months preceding and following this investigation.
AB - Background In this study we examined the difference in patient INR values as measured by the POCT CoaguChek XS device and central laboratory Stago Evolution and Siemens BCS XP analyzers. Methods This study composed of 100 warfarin therapy patients and 20 coagulation normal subjects, showed that the difference between the POCT and clinical laboratory values increased with increasing INR and was exacerbated by the use of different thromboplastin reagents by the POCT and central lab. Results The CoaguChek XS and on-site Stago analyzers which used human recombinant (ISI = 1.01) and rabbit brain thromboplastin (ISI = 1.25), respectively, showed reasonable agreement for INR < 3.0 (k = 0.62) but significant difference for INR ≥ 3.0 (k = 0.10). In contrast, the CoaguChek XS and Siemens BCS XP, which both employed human recombinant thromboplastin (BCS ISI = 1.02), showed greater agreement for the complete range INR values (INR < 3.0 k = 0.84; INR ≥ 3.0 k = 0.70). ECAA Poller calibrant data showed the automated instruments were performing as expected, indicating that ISI calibrations were correct but insufficient to standardize the INR values for the different thromboplastin methods across the full range of measured INRs. Central lab verification of POCT INR > 5.0 with the Stago Evolution prevented adverse treatment events for the warfarin therapy patients in the six months preceding and following this investigation.
KW - Anticoagulation
KW - CoaguChek XS
KW - INR
KW - International normalized ratio
KW - POCT
KW - Point of care testing
UR - http://www.scopus.com/inward/record.url?scp=85026860042&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85026860042&partnerID=8YFLogxK
U2 - 10.1016/j.cca.2017.07.027
DO - 10.1016/j.cca.2017.07.027
M3 - Article
C2 - 28774502
AN - SCOPUS:85026860042
SN - 0009-8981
VL - 472
SP - 139
EP - 145
JO - Clinica Chimica Acta
JF - Clinica Chimica Acta
ER -